Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The low molecular weight compound PRIMA-1MET reactivates mutant p53 and triggers mutant p53-dependent apoptosis in human tumor cells. We investigated the effect of PRIMA-1MET on global gene expression using microarray analysis of Saos-2 cells expressing His273 mutant p53 and parental p53 null Saos-2 cells. PRIMA-1MET affected transcription of a significantly larger number of genes in the mutant p53-expressing cells compared to the p53 null cells. Genes affected by PRIMA-1MET in a mutant p53-dependent manner include the cell-cycle regulators GADD45B and 14-3-3γ and the pro-apoptotic Noxa. Several of the affected genes are known p53 target genes and/or contain p53 DNA-binding motifs. We also found mutant p53-dependent disruption of the cytoskeleton, as well as transcriptional activation of the XBP1 gene and cleavage of its mRNA, a marker for endoplasmic reticulum stress. Our data show that PRIMA-1MET induces apoptosis through multiple transcription-dependent and -independent pathways. Such integral engagement of multiple pathways leading to apoptosis is consistent with restoration of wild-type properties to mutant p53 and is likely to reduce the risk of drug resistance development in clinical applications of PRIMA-1MET.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 5×
“PRIMA-1MET has been shown to restore wild-type conformation to mutant p53, resulting in upregulation of p53 targets such as p21, MDM2, and Bax (Bykov et al., 2002, 2005).”
BackgroundInfluentialRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Under normal conditions, p53 is expressed at low levels because of negative feedback regulation by MDM2 (Haupt et al., 1997; Kubbutat et al., 1997).”
BackgroundDynamic interaction of BiP and ER stress transducers in the unfolded-protein response
Bertolotti, A., Zhang, Y., Hendershot, L. M., Harding, H. P., & Ron, D. (2000) · Nature Cell Biology · doi:10.1038/35014014 · Cited by 2,860
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“PRIMA-1MET has been shown to restore wild-type conformation to mutant p53, resulting in upregulation of p53 targets such as p21, MDM2, and Bax (Bykov et al., 2002, 2005).”
BackgroundInfluentialSelf-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“…suppressor activity as well as the acquisition of novel functions (so called gain-of-function) attributed to some p53 mutants, often counteracts the effect of cancer treatment, as many anti-cancer drugs attack tumors by activating p53-dependent apoptosis (Bunz et al., 1999; Andersson et al., 2005).”
BackgroundVousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 1×
“…pro-apoptotic and antiautophagic activity in the cytoplasm where it localizes to the mitochondria (reviewed by Green and Kroemer, 2009). p53 is also involved in processes such as DNA repair (Livneh, 2006), cellular senescence (Xue et al., 2007), and metabolism (Vousden and Ryan, 2009).”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Self-citationGaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Self-citationLi, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57 · cited 1×
“This may explain why earlier studies have shown PRIMA-1MET induced apoptosis through Bax and the mitochondrial pathway (Chipuk et al., 2003; Wang et al., 2007; Shen et al., 2008) or the JNK pathway in a mutant p53-dependent manner (Li et al., 2005).”
Background
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“386 400 However, growing evidence suggests that APR-246 exerts its effects through a multitude of pathways independent of p53, 401 – 404 such as downregulating glutathione concentrations in tumor cells, 405,406 regulating oxidation-reduction homeostasis 407 – 409 in tumor cells to trigger…”
BackgroundTargeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Self-citationTargeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Self-citationFarnebo, M., Bykov, V. J. N., & Wiman, K. G. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.152 · Cited by 268
Self-citation
Metadata
- Authors
- Lambert, J. M. R., Moshfegh, A., Hainaut, P., Wiman, K. G., & Bykov, V. J. N.
- Venue
- Oncogene
- Published
- 2009-11-30
- Volume
- 29
- Issue
- 9
- Pages
- 1329-1338
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2058624670
- Cited by
- 106
- References
- 14
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.